Author: Wilson Kenneth S Malfair Taylor Suzanne C
Publisher: Informa Healthcare
ISSN: 1742-5255
Source: Expert Opinion on Drug Metabolism and Toxicology, Vol.5, Iss.11, 2009-11, pp. : 1447-1454
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
By Cutsem E.V.
Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. :
Indirect costs lower with raltitrexed
Inpharma, Vol. 1, Iss. 1242, 2000-01 ,pp. :
Clinical and Preclinical Pharmacokinetics of Raltitrexed
By Clarke S.J.
Clinical Pharmacokinetics, Vol. 39, Iss. 6, 2000-12 ,pp. :
Indirect costs lower with raltitrexed
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 267, 2000-01 ,pp. :
Raltitrexed + cisplatin stabilise HRQOL in mesothelioma
Inpharma, Vol. 1, Iss. 1530, 2006-01 ,pp. :